Li Ruan

Li Ruan

Auto-generated profile, based on publicly available information

Li Ruan

Biotech Center for Viral Disease Emergency, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China,

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2012 in Virology Journal
Verified
Journal Article
Open access
PDF file
BHBaoying HUANG
Baoying HUANG
WWWenling Wang
Wenling Wang
RLRenqing Li
Renqing Li
XWXiuping Wang
Xiuping Wang
TJTao Jiang
Tao Jiang
LRLi Ruan
Li Ruan
Background: Immunity to conserved viral antigens is an attractive approach to develop a universal vaccine against epidemic and pandemic influenza. A nucleoprotein (NP)-based vaccine has been explored and preliminary studies have shown promise. However, no study has explored the immunity and cross-protective efficacy of recombinant NP derived fromEscherichia colicompared with recombinant vaccinia virus (Tiantan).Methods: Recombinant NP protein (rNP) from influenza virus A/Jingke/30/95(H3N2) was obtained fromE. coliand recombinant vaccinia virus (Tiantan) RVJ1175NP. Purified rNP without adjuvant and RVJ1175NP were used to immunize BALB/c mice intramuscularly. Humoral immune responses were detected by ELISA, while cell-mediated immune responses were measured byex vivoIFN-γ ELISPOT andin vivocytotoxicity assays. The cross-protective efficacy was assessed by a challenge with a heterosubtype of influenza virus A/PR/8/34(H1N1).Results: Our results demonstrate that a high dose (90 μg) of rNP induced NP-specific antibodies and T cell responses that were comparable with those of RVJ1175NP in mice. Importantly, the survival ratio (36, 73, and 78%) of the vaccinated mice after the influenza virus A/PR/8/34(H1N1) challenge was rNP vaccine dose-dependent (10, 30, and 90 μg, respectively), and no significant differences were observed between the rNP- and RVJ1175NP-immunized (91%) mice.Conclusions: Influenza A virus NP derived fromE. colior recombinant vaccinia (Tiantan) virus elicited cross-protection against influenza virus in mice, and the immune response and protective efficacy of rNP were comparable to RVJ1175NP. These data provide a basis for the use of prokaryotically expressed NP as a candidate universal influenza vaccine.

15 June 2011 in Virology Journal
Verified
Journal Article
Open access
PDF file
LZLi Zhao
Li Zhao
BLBinlei Liu
Binlei Liu
JRJiao Ren
Jiao Ren
JFJing Feng
Jing Feng
ZPZheng Pang
Zheng Pang
LRLi Ruan
Li Ruan
Background: Persistent infection with high-risk human papillomavirus (HPV) is a predominant cause of cervical cancer, and HPV16 and HPV18 occur in 50% and 20% of cervical cancer cases, respectively. The viral oncogenes E6 and E7 are constitutively expressed by HPV-associated tumour cells and can therefore be used as target antigens for immunotherapy. In this study, we constructed a recombinant vaccinia virus co-expressing the HPV16/18 E7E6 fusion proteins (rVVJ16/18E7E6) for use as a therapeutic vaccine for the treatment of HPV16+ and HPV18+ cancers. Methods: We constructed a bivalent recombinant vaccinia virus expressing modified E7E6 fusion proteins of HPV type 16 and 18 (rVVJ16/18E7E6) based on the vaccinia virus Tiantan strain. We then defined the cellular immune responses to the virus in mice and rhesus monkeys and assessed antitumour efficacy of these responses in mice using the TC-1 tumour challenge model. Results: Our data demonstrated that rVVJ16/18E7E6 was able to elicit varying levels of CD8+ T cell immune responses and lysis of target cells in mice in response to peptides HPV16E749-57 and HPV18E667-75. Furthermore, the virus was also able to induce anti-tumour responses in the HPV16+ TC-1 tumour challenge model, including partial protection (30-40%) and delayed tumour appearance. In addition, the virus was able to induce immune responses in rhesus monkeys. Conclusions: The recombinant vaccinia virus rVVJ16/18E7E6 can generate clear and significant cellular immunity in both mice and rhesus monkeys. These data provide a basis for the use of this recombinant virus as a potential vaccine candidate for further study.

4 November 2011 in Virology Journal
Verified
Journal Article
Open access
PDF file
JGJie Guan
Jie Guan
BWBo Wen
Bo Wen
YDYao Deng
Yao Deng
KZKe Zhang
Ke Zhang
HCHong Chen
Hong Chen
WTWenjie Tan
Wenjie Tan
Background: An effective vaccine and new therapeutic methods for hepatitis C virus (HCV) are needed, and a potent HCV vaccine must induce robust and sustained cellular-mediated immunity (CMI). Research has indicated that adenoviral and vaccinia vectors may have the ability to elicit strong B and T cell immune responses to target antigens. Results: A recombinant replication-defective adenovirus serotype 5 (rAd5) vector, rAd5-CE1E2, and a recombinant Tian Tan vaccinia vector, rTTV-CE1E2, were constructed to express the HCV CE1E2 gene (1-746 amino acid HCV 1b subtype). Mice were prime-immunised with rAd5-CE1E2 delivered via intramuscular injection (i.m.), intranasal injection (i.n.), or intradermal injection (i.d.) and boosted using a different combination of injection routes. CMI was evaluated via IFN-γ ELISPOT and ICS 2 weeks after immunisation, or 16 weeks after boost for long-term responses. The humoral response was analysed by ELISA. With the exception of priming by i.n. injection, a robust CMI response against multiple HCV antigens (core, E1, E2) was elicited and remained at a high level for a long period (16 weeks post-vaccination) in mice. However, i.n. priming elicited the highest anti-core antibody levels. Priming with i.d. rAd5-CE1E2 and boosting with i.d. rTTV-CE1E2 carried out simultaneously enhanced CMI and the humoral immune response, compared to the homologous rAd5-CE1E2 immune groups. All regimens demonstrated equivalent cross-protective potency in a heterologous surrogate challenge assay based on a recombinant HCV (JFH1, 2a) vaccinia virus. Conclusions: Our data suggest that a rAd5-CE1E2-based HCV vaccine would be capable of eliciting an effective immune response and cross-protection. These findings have important implications for the development of T cell-based HCV vaccine candidates.

1 January 2010
Verified
Journal Article
Closed access
HCHong Chen
Hong Chen
YDYao Deng
Yao Deng
WTWenjie Tan
Wenjie Tan
WWWen Wang
Wen Wang
XYXiao Yin
Xiao Yin
LRLi Ruan
Li Ruan

1 July 2008
Verified
Journal Article
Closed access
RLRou-Jian Lu
Rou-Jian Lu
LZLing-Lin Zhang
Ling-Lin Zhang
WTWen-Jie Tan
Wen-Jie Tan
WZWeimin Zhou
Weimin Zhou
ZWZhong Wang
Zhong Wang
LRLi Ruan
Li Ruan

1 September 2007
Verified
Journal Article
Closed access
WWWen-Ling Wang
Wen-Ling Wang
BHBao-Ying Huang
Bao-Ying Huang
YDYao Deng
Yao Deng
XWXiu-Ping Wang
Xiu-Ping Wang
WTWen-Jie Tan
Wen-Jie Tan
LRLi Ruan
Li Ruan